I thought I'd do a little summary like I did for
the Ariad thread over here...I'll just do the last
hundred posts or so, except for one early in the
thread--once again, I do not mean to embarrass anybody,
I merely want to help put things in perspective.
Message 744390
so, we pick the story up again about eight months ago...
where the stock doubled in a short period of time.
CTII a good stem cell play. Sympathy with GERN. Stock moving.
11/07/98 Copyright 1998, The Washington Post Co. Shares of genetic research pioneer Geron Corp. soared yesterday, and stocks of many other drug and biotechnology firms got a boost as well, as small investors went into a buying frenzy over breakthroughs that may permit scientists to grow endless supplies of any kind of human cell.
(CTII appears in the article)
Message 6337621
CytoTherapeutics Inc. plans to treat Parkinson's disease using a neural stem cell. " We're not talking about something 10 to 20 years away, like GERON, " says CEO Richard M. Rose, MD. Says James D McCament, editor of Medical Technology Stock Letter, "CytoTherapeutics is much closer to the clinic and more significant from an investment standpoint"
Ground Floor's 1999 Doublers Portfolio--CTII one of six
CytoTherapeutics Obtains Exclusive, Worldwide Licenses to Technology for Discovering Pancreatic Stem/Progenitor Cells
LINCOLN, R.I.--(BW HealthWire)--Dec. 21, 1998--
Proprietary Technology May Speed Discovery
Useful in Treatment of Diabetes
LINCOLN, R.I.--(BW HealthWire)--Dec. 22, 1998--CytoTherapeutics, Inc.
Nasdaq:CTII - news) announced that the U.S. Patent and Trademark
Office has granted patent No. 5,851,832, covering methods for expanding human neural stem cell cultures, for compositions of human neural stem cell cultures expanded by these methods, and for use of these cultures in human transplantation and remyelination.
I suggest buying a few things that look the most interesting in this area, and being patient.
WSJ article on biotechnology. January 5, 1999
Biotech Investor Shares Dreams, Frustrations of Little Companies
(I was really whacked out when I wrote a response to that
article, and sent it off to the WSJ, very embarrassing,
Rick responded with...)
Gaaaaaawwwwwwd, Mike's nuts. Glad he's on our side.
Wake-up CTII! It is time to do some serious work!
Miljenko
Stepping aside from the neural stem cells for a moment, I see also that ctii had a deal going with Astra--something called CereCRIB for severe chronic pain.
url with patent numbers
Message 7197222
Good questions from Miljenko
Message 7201177
M. Levin done very good job at MLNM (hope he will continue in future), so he may be a good addition to CTII board members. His knowledge and
experience are of great value and it is a big + for CTII.
they have a real reasonable chance of being a big CNS player over the next few years. My other is cnsi...and that one got delisted yesterday, so what the hell do I know?
What is new? CTII reinvented itself in 9/97 with Rose/Weissman.
While the Vescovi research currently lies outside of the scope of
their existing agreements with Neurospheres, all other the roads to
commercializing the standard applications of the human neural stem cell (as exemplified by the research of Snyder) must pass through the heart of their existing patent neighborhood.
With any luck we will here something in the next few months about the IIB pain trial with Astra, and anything more that comes of the stem
cells will be gravy...a lot of gravy.
Jim McCamant (Medical Tech Stock Letter) in issue # 361 announced that; " We know that the they are in partnership conversations with at least two companies for a deal in the stem cell area.
Could not take the pain anymore...let myself get stopped out of 5000
of my 8000 shares
the article (Encapsulated Cells as Therapy) is on pg. 76 0f the April Scientific American. One of the writers is Aebischer, who used to work for CTII and may still but I can't verify it. CTII is mentioned on page 80
Relationship between Millennium Pharm. (MLNM) and CTII (and glowing
mention of MLNM in 4/12/99 issue of Barron's).
Mike, in my experience, whenever a founder resigns after disagreement
w/management, it is not a good sign for shareholders. I got out (above
$1/share, but barely) at the open this a.m.
I may have to get some more shares now that it has bottomed out.
This company has very little cash left. IMO delisting means little, they either get bought, run out of cash, or pull a rabbit's stem cells out of a hat. This stock is a call option on the buyout or the rabbit.
I'll take the rabbit for a dollar Dave.
either I'm going to look pretty silly a year from now, or I'll look like the bravest, luckiest biotech groupie here on SI.
What little information they provide on the spinal implant passed my sniff test.
I've worked closely with Irv Weissman. He hired me at SyStemix, although I didn't stay long. IMO, he wouldn't do anything unless he felt that it was of benefit to CTII shareholders in general.
what exactly are the new FDA rules for xenotransplantation?
A lot going on, and good connections; Weissman/Stanford, Gage/Salk Institute, Anderson/Calif. Institute of Technology, Sarvetnick/Scripps.
Says the results of pain trial is due out in June. The story was featured in the May 24-30, 1999 issue of Providence Business News.
Stem Cells May Restore Neurons
The Company and Cognetix are presently discussing proposed revisions to their relationship under the agreement.
____________
One final comment--I do not know if this little exercise is worthwhile or not when it comes from me, having no education in biology, genetics, chemistry, much less organic chemistry or any of the medical sciences. However...as long as I have no reason to move to some sort of a private listserve sort of investors club, I'll continue to do exactly what SI seems to be useful for--basic detective work--and due diligence 101. I think slogging through the blurbs on these threads is not a bad way to at least get the feel for a company--it's not sophisticated like what they do at the brokerage houses, but it is good enough for me, hope it helps others out too.
Apologies to Neuroinvestment for giving that first url, but
I think it is important to see how the biotech>CNS subsector has been
brutalized by Wall Street.
--Mike |
